Michaela Gold
@michaelagold.bsky.social
Innovation at Seaport Therapeutics. PhD at MIT
Reposted by Michaela Gold
We're featured in @natbiotech.nature.com's “Editor’s Pick” for our work developing #neuropsychiatric medicines using our proprietary Glyph platform. Read about how we're advancing novel therapies with clinically validated mechanisms for depression & anxiety bit.ly/47f4jke
Each year, we highlight companies that received sizeable early-stage funding in the previous year. @seaporttx.bsky.social is modifying central nervous system drugs for delivery through the lymphatic system, bypassing first-pass liver metabolism
Editor’s Pick: Seaport Therapeutics - Nature Biotechnology
Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Seaport Therapeutics is modifying central nervous system drugs for delivery throug...
go.nature.com
August 4, 2025 at 5:11 PM
We're featured in @natbiotech.nature.com's “Editor’s Pick” for our work developing #neuropsychiatric medicines using our proprietary Glyph platform. Read about how we're advancing novel therapies with clinically validated mechanisms for depression & anxiety bit.ly/47f4jke
We had a great time presenting at ISCTM!
Our team was at #ISCTM to present a meta-analysis exploring the impact of clinical trial design factors on placebo effect in #MDD trials. Key finding links number & frequency of clinician-administered assessments to increased placebo response. Read more: bit.ly/3Qsz8bx
February 21, 2025 at 1:49 PM
We had a great time presenting at ISCTM!